MARGINAL ZONE LYMPHOMA
Clinical trials for MARGINAL ZONE LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new MARGINAL ZONE LYMPHOMA trials appear
Sign up with your email to follow new studies for MARGINAL ZONE LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells show promise against Tough-to-Treat lymphoma
Disease control CompletedThis study tested a treatment called axicabtagene ciloleucel (a CAR T-cell therapy) in 159 adults with follicular or marginal zone lymphoma that had returned or stopped responding after at least two prior treatments. The therapy works by reprogramming a patient's own immune cells…
Matched conditions: MARGINAL ZONE LYMPHOMA
Phase: PHASE2 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated May 01, 2026 15:57 UTC
-
New drug combo may make Half-Matched transplants safer for blood cancer patients
Disease control CompletedThis study tested whether replacing a standard transplant drug (cyclophosphamide) with a different drug (bendamustine) could make half-matched bone marrow transplants safer for people with blood cancers like leukemia and lymphoma. About 50 patients took part. The goal was to redu…
Matched conditions: MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: University of Arizona • Aim: Disease control
Last updated May 01, 2026 15:57 UTC
-
New hope for tough blood cancers: experimental drug PRT2527 enters human testing
Disease control CompletedThis early-stage trial tested a new drug called PRT2527, alone or combined with other drugs (zanubrutinib or venetoclax), in 86 people with blood cancers that returned or didn't respond to standard treatments. The main goals were to check safety, find the best dose, and see if th…
Matched conditions: MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC